Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.

Strategic Leadership

Latest resources

Certara Reports First Quarter 2025 Financial Results

Certara to Participate in Upcoming Investor Conferences

Certara Announces Second Annual Certainty U.S. Event

Featured resource

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Upcoming strategic leadership webinars

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Popular resources

Certara Announces Second Annual Certainty U.S. Event

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization

Introducing the new Certara.com: Transforming drug development for good, together.

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan

Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities

Meet our experts at the following events

Bio International Convention 2025

All Strategic Leadership resources

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Bio International Convention 2025

Introducing the new Certara.com: Transforming drug development for good, together.

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product

Pharma Exec: MDMA Therapy for Mental Health Conditions

Empower Your Students with Industry-Leading Software

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities

Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report

FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies

The Uncertain Path Forward for Psychedelic Medicine

Overcoming CMC Challenges in Cell and Gene Therapy: Part I

Newsletter sign up

Quick links

Solutions

Contact